Anders Nissen Bonde1, Gregory Y H Lip2, Anne-Lise Kamper2, Emil L Fosbøl2, Laila Staerk2, Nicholas Carlson2, Christian Torp-Pedersen2, Gunnar Gislason2, Jonas Bjerring Olesen2. 1. From the Department of Cardiology, Copenhagen University Hospital Gentofte, Denmark (A.N.B., L.S., N.C., G.G., J.B.O.); Institute of Cardiovascular Sciences, University of Birmingham, City Hospital, United Kingdom (G.Y.H.L.); Department of Nephrology (A.-L.K.) and Department of Cardiology (E.L.F.), Copenhagen University Hospital Rigshospitalet, Denmark; Department of Nephrology, Copenhagen University Hospital Herlev, Denmark (N.C.); Institute of Health, Science and Technology, Aalborg University, Aalborg, Denmark (C.T.-P.); The Danish Heart Foundation, Copenhagen, Denmark (G.G.); and The National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark (G.G.). andersnissenbonde@gmail.com. 2. From the Department of Cardiology, Copenhagen University Hospital Gentofte, Denmark (A.N.B., L.S., N.C., G.G., J.B.O.); Institute of Cardiovascular Sciences, University of Birmingham, City Hospital, United Kingdom (G.Y.H.L.); Department of Nephrology (A.-L.K.) and Department of Cardiology (E.L.F.), Copenhagen University Hospital Rigshospitalet, Denmark; Department of Nephrology, Copenhagen University Hospital Herlev, Denmark (N.C.); Institute of Health, Science and Technology, Aalborg University, Aalborg, Denmark (C.T.-P.); The Danish Heart Foundation, Copenhagen, Denmark (G.G.); and The National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark (G.G.).
Abstract
BACKGROUND AND PURPOSE: We sought to determine the risk of stroke/thromboembolism and bleeding associated with reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin treatment in specific estimated glomerular filtration rate (eGFR) groups. METHODS: We conducted a register-based cohort study and included patients discharged with nonvalvular atrial fibrillation from 1997 to 2011 with available eGFR. RESULTS: A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated with higher risk of stroke/thromboembolism and bleeding. Use of warfarin was associated with higher bleeding risk in all eGFR groups; hazard ratios 1.23 (95% confidence interval [CI], 0.97-1.56), 1.26 (95% CI, 1.14-1.40), 1.18 (95% CI, 1.07-1.31), 1.11 (95% CI, 0.87-1.42), 2.01 (95% CI, 1.14-3.54) in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m2, respectively. Use of warfarin was associated with lower risk of stroke/thromboembolism in patients with eGFR ≥15 mL/min per 1.73 m2; hazard ratios 0.57 (95% CI, 0.43-0.76), 0.57 (95% CI, 0.51-0.64), 0.48 (95% CI, 0.44-0.54), 0.60 (95% CI, 0.45-0.80) in patients with eGFR ≥90, 60 to 89, 30 to 59, and 15 to 29 mL/min per 1.73 m2, respectively. Use of warfarin was not associated with lower risk of stroke/thromboembolism in patients with eGFR<15 mL/min per 1.73 m2; hazard ratio 1.18 (95% CI, 0.58-2.40). CONCLUSIONS: In patients with atrial fibrillation, the risk of stroke and bleeding was associated with levels of renal function. Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke in patients with eGFR≥15 mL/min per 1.73 m2.
BACKGROUND AND PURPOSE: We sought to determine the risk of stroke/thromboembolism and bleeding associated with reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin treatment in specific estimated glomerular filtration rate (eGFR) groups. METHODS: We conducted a register-based cohort study and included patients discharged with nonvalvular atrial fibrillation from 1997 to 2011 with available eGFR. RESULTS: A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated with higher risk of stroke/thromboembolism and bleeding. Use of warfarin was associated with higher bleeding risk in all eGFR groups; hazard ratios 1.23 (95% confidence interval [CI], 0.97-1.56), 1.26 (95% CI, 1.14-1.40), 1.18 (95% CI, 1.07-1.31), 1.11 (95% CI, 0.87-1.42), 2.01 (95% CI, 1.14-3.54) in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m2, respectively. Use of warfarin was associated with lower risk of stroke/thromboembolism in patients with eGFR ≥15 mL/min per 1.73 m2; hazard ratios 0.57 (95% CI, 0.43-0.76), 0.57 (95% CI, 0.51-0.64), 0.48 (95% CI, 0.44-0.54), 0.60 (95% CI, 0.45-0.80) in patients with eGFR ≥90, 60 to 89, 30 to 59, and 15 to 29 mL/min per 1.73 m2, respectively. Use of warfarin was not associated with lower risk of stroke/thromboembolism in patients with eGFR<15 mL/min per 1.73 m2; hazard ratio 1.18 (95% CI, 0.58-2.40). CONCLUSIONS: In patients with atrial fibrillation, the risk of stroke and bleeding was associated with levels of renal function. Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke in patients with eGFR≥15 mL/min per 1.73 m2.
Authors: Andres Escobar; Ahmed M Salem; Kodwo Dickson; Tami N Johnson; Kathyrn J Burk; Lara Bashoura; Saadia A Faiz Journal: Support Care Cancer Date: 2022-05-17 Impact factor: 3.359
Authors: Juan Jesus Carrero; Marco Trevisan; Manish M Sood; Peter Bárány; Hong Xu; Marie Evans; Leif Friberg; Karolina Szummer Journal: Clin J Am Soc Nephrol Date: 2018-07-20 Impact factor: 8.237
Authors: Shinya Goto; Pantep Angchaisuksiri; Jean-Pierre Bassand; A John Camm; Helena Dominguez; Laura Illingworth; Harry Gibbs; Samuel Z Goldhaber; Shinichi Goto; Zhi-Cheng Jing; Sylvia Haas; Gloria Kayani; Yukihiro Koretsune; Toon Wei Lim; Seil Oh; Jitendra P S Sawhney; Alexander G G Turpie; Martin van Eickels; Freek W A Verheugt; Ajay K Kakkar Journal: J Am Heart Assoc Date: 2019-02-05 Impact factor: 5.501
Authors: Anna Michalska; Iwona Gorczyca; Magdalena Chrapek; Agnieszka Kapłon-Cieślicka; Beata Uziębło-Życzkowska; Katarzyna Starzyk; Olga Jelonek; Monika Budnik; Monika Gawałko; Paweł Krzesiński; Agnieszka Jurek; Piotr Scisło; Janusz Kochanowski; Marek Kiliszek; Grzegorz Gielerak; Krzysztof J Filipiak; Grzegorz Opolski; Beata Wożakowska-Kapłon Journal: Medicine (Baltimore) Date: 2020-06-19 Impact factor: 1.817